COVID-19: Learn the precautions Scripps is taking for safe, in-person visits Learn more
Continuous Glucose Monitoring Study
In response to the COVID pandemic, Scripps Health has temporarily suspended enrollment for all clinical trials. Exceptions will exist for trials with curative intent, life-saving treatment or when no standard of care exists. For questions, please call Scripps Office for the Protection of Research Subjects at 858-678-6402.
Athena Philis-Tsimikas, M.D.
The MOBILE study looks to see how blood sugar is managed when using a Continuous Glucose Monitor (CGM) compared to fingerstick testing in people with Type 2 Diabetes taking long-acting insulin once or twice a day.
Be 30 years old or older.
Have been taking long-acting insulin for the last 6 months.
Have stable medications for the last 3 months.
Have a smartphone that works with the devices used in the study (smartphone compatibility will be assessed).
Have diabetes managed by a primary care physician (PCP), NP, PA, etc.
Have diabetes managed by an endocrinologist.
A CGM measures the glucose level in the fluid under the skin. It consists of a sensor which is inserted into the skin, a transmitter attached to the sensor and a display device. Every 5 minutes, the transmitter sends glucose readings to the display device.